Mostrar el registro sencillo del ítem

dc.contributor.author
Murali, Mahadevamurthy  
dc.contributor.author
Gowtham, Hittanahallikoppal Gajendramurthy  
dc.contributor.author
Ansari, Mohammad Azam  
dc.contributor.author
Alomary, Mohammad N.  
dc.contributor.author
Alghamdi, Saad  
dc.contributor.author
Almehmadi, Mazen  
dc.contributor.author
Singh, Sudarshana Brijesh  
dc.contributor.author
Shilpa, Natarajamurthy  
dc.contributor.author
Aiyaz, Mohammed  
dc.contributor.author
Kalegowda, Nataraj  
dc.contributor.author
Ledesma, Ana Estela  
dc.contributor.author
Amruthesh, Kestur Nagaraj  
dc.date.available
2022-07-22T19:52:54Z  
dc.date.issued
2022-06  
dc.identifier.citation
Murali, Mahadevamurthy; Gowtham, Hittanahallikoppal Gajendramurthy; Ansari, Mohammad Azam; Alomary, Mohammad N.; Alghamdi, Saad; et al.; Repositioning Therapeutics for SARS-CoV-2: Virtual Screening of Plant-based Anti-HIV Compounds as Possible Inhibitors against COVID-19 Viral RdRp; Bentham Science Publishers; Current Pharmaceutical Design; 28; 12; 6-2022; 969-980  
dc.identifier.issn
1381-6128  
dc.identifier.uri
http://hdl.handle.net/11336/162959  
dc.description.abstract
Background: Coronavirus disease 2019 (COVID-19) has caused a global pandemic with a high mortality and morbidity rate worldwide. The COVID-19 vaccines that are currently in development or already approved are expected to provide at least some protection against the emerging variants of the virus, but the mutations may reduce the efficacy of the existing vaccines. Purified phytochemicals from medicinal plants provide a helpful framework for discovering new therapeutic leads as they have long been employed in traditional medicine to treat many disorders. Objective: The objectives of the study are to exploit the anti-HIV bioactive compounds against SARS-CoV-2 RNA-dependent RNA polymerase (RdRp) through molecular docking studies and to evaluate the Absorption, Distribution, Metabolism, Excretion, and Toxicity (ADMET) properties of potential compounds. Methods: Molecular docking was performed to study the interaction of ligands with the target sites of RdRp protein (PDB: 6M71) using AutoDock Vina. The ADMET properties of potential compounds were predicted using the pkCSM platform. Results: A total of 151 phytochemicals derived from the medicinal plants with recognized antiviral activity and 18 anti-HIV drugs were virtually screened against COVID-19 viral RdRp to identify putative inhibitors that facilitate the development of potential anti-COVID-19 drug candidates. The computational studies identified 34 compounds and three drugs inhibiting viral RdRp with binding energies ranging from -10.2 to -8.5 kcal/mol. Among them, five compounds, namely Michellamine B, Quercetin 3-O-(2'',6''-digalloyl)-beta-Dgalactopyranoside, Corilagin, Hypericin, and 1,2,3,4,6-Penta-O-galloyl-beta-D-glucose residues, bound efficiently with the binding site of RdRp. Besides, Lopinavir, Maraviroc, and Remdesivir drugs also inhibited SARS-CoV-2 polymerase. In addition, the ADMET properties of top potential compounds were also predicted in comparison to the drugs. Conclusion: The present study suggested that these potential drug candidates can be further subjected to in vitro and in vivo studies that may help develop effective anti-COVID-19 drugs.  
dc.format
application/pdf  
dc.language.iso
eng  
dc.publisher
Bentham Science Publishers  
dc.rights
info:eu-repo/semantics/openAccess  
dc.rights.uri
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/  
dc.subject
ANTI-COVID-19 DRUGS  
dc.subject
ANTI-HIV COMPOUNDS  
dc.subject
CORONAVIRUSES  
dc.subject
HYPERICIN  
dc.subject
MOLECULAR DOCKING  
dc.subject
RNA-DEPENDENT RNA POLYMERASE  
dc.subject
COVID-19  
dc.subject.classification
Otras Ciencias Químicas  
dc.subject.classification
Ciencias Químicas  
dc.subject.classification
CIENCIAS NATURALES Y EXACTAS  
dc.title
Repositioning Therapeutics for SARS-CoV-2: Virtual Screening of Plant-based Anti-HIV Compounds as Possible Inhibitors against COVID-19 Viral RdRp  
dc.type
info:eu-repo/semantics/article  
dc.type
info:ar-repo/semantics/artículo  
dc.type
info:eu-repo/semantics/publishedVersion  
dc.date.updated
2022-07-21T15:58:12Z  
dc.journal.volume
28  
dc.journal.number
12  
dc.journal.pagination
969-980  
dc.journal.pais
Estados Unidos  
dc.journal.ciudad
Oak Park  
dc.description.fil
Fil: Murali, Mahadevamurthy. University of Mysore; India  
dc.description.fil
Fil: Gowtham, Hittanahallikoppal Gajendramurthy. University of Mysore; India  
dc.description.fil
Fil: Ansari, Mohammad Azam. Bin Faisal University; Arabia Saudita  
dc.description.fil
Fil: Alomary, Mohammad N.. King Abdulaziz City for Science and Technology; Arabia Saudita  
dc.description.fil
Fil: Alghamdi, Saad. Umm Al qura University; Arabia Saudita  
dc.description.fil
Fil: Almehmadi, Mazen. Taif Universisty; Arabia Saudita  
dc.description.fil
Fil: Singh, Sudarshana Brijesh. University of Mysore; India  
dc.description.fil
Fil: Shilpa, Natarajamurthy. University of Mysore; India  
dc.description.fil
Fil: Aiyaz, Mohammed. University of Mysore; India  
dc.description.fil
Fil: Kalegowda, Nataraj. University of Mysore; India  
dc.description.fil
Fil: Ledesma, Ana Estela. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet Noa Sur. Centro de Investigación en Biofísica Aplicada y Alimentos. - Universidad Nacional de Santiago del Estero. Centro de Investigación en Biofísica Aplicada y Alimentos; Argentina  
dc.description.fil
Fil: Amruthesh, Kestur Nagaraj. University of Mysore; India  
dc.journal.title
Current Pharmaceutical Design  
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/doi/https://dx.doi.org/10.2174/1381612828666220428120939  
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/url/https://www.eurekaselect.com/article/123019